These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


194 related items for PubMed ID: 26563652

  • 1. Development and characterization of human monoclonal antibodies that neutralize multiple TGFβ isoforms.
    Bedinger D, Lao L, Khan S, Lee S, Takeuchi T, Mirza AM.
    MAbs; 2016; 8(2):389-404. PubMed ID: 26563652
    [Abstract] [Full Text] [Related]

  • 2. Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy.
    Lai YD, Wu YY, Tsai YJ, Tsai YS, Lin YY, Lai SL, Huang CY, Lok YY, Hu CY, Lai JS.
    Int J Mol Sci; 2016 Feb 05; 17(2):214. PubMed ID: 26861297
    [Abstract] [Full Text] [Related]

  • 3. Structures of a pan-specific antagonist antibody complexed to different isoforms of TGFβ reveal structural plasticity of antibody-antigen interactions.
    Moulin A, Mathieu M, Lawrence C, Bigelow R, Levine M, Hamel C, Marquette JP, Le Parc J, Loux C, Ferrari P, Capdevila C, Dumas J, Dumas B, Rak A, Bird J, Qiu H, Pan CQ, Edmunds T, Wei RR.
    Protein Sci; 2014 Dec 05; 23(12):1698-707. PubMed ID: 25209176
    [Abstract] [Full Text] [Related]

  • 4. Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells.
    Zhong Z, Carroll KD, Policarpio D, Osborn C, Gregory M, Bassi R, Jimenez X, Prewett M, Liebisch G, Persaud K, Burtrum D, Wang S, Surguladze D, Ng S, Griffith H, Balderes P, Doody J, Schwartz JD, Youssoufian H, Rowinsky EK, Ludwig DL, Witte L, Zhu Z, Wu Y.
    Clin Cancer Res; 2010 Feb 15; 16(4):1191-205. PubMed ID: 20145179
    [Abstract] [Full Text] [Related]

  • 5. Isolation of high-affinity, neutralizing anti-idiotype antibodies by phage and ribosome display for application in immunogenicity and pharmacokinetic analyses.
    Chin SE, Ferraro F, Groves M, Liang M, Vaughan TJ, Dobson CL.
    J Immunol Methods; 2015 Jan 15; 416():49-58. PubMed ID: 25449532
    [Abstract] [Full Text] [Related]

  • 6. Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency.
    Yang Y, Guo Q, Xia M, Li Y, Peng X, Liu T, Tong X, Xu J, Guo H, Qian W, Hou S, Dai J, Wang H, Liu R, Guo Y.
    MAbs; 2015 Jan 15; 7(2):440-50. PubMed ID: 25679409
    [Abstract] [Full Text] [Related]

  • 7. Development of an in vitro potency assay for therapeutic TGFbeta antagonists: the A549 cell bioassay.
    Rapoza ML, Fu D, Sendak RA.
    J Immunol Methods; 2006 Oct 20; 316(1-2):18-26. PubMed ID: 17010369
    [Abstract] [Full Text] [Related]

  • 8. A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.
    Lam S, Nyo M, Phuektes P, Yew CW, Tan YJ, Chu JJ.
    MAbs; 2015 Oct 20; 7(6):1178-94. PubMed ID: 26305993
    [Abstract] [Full Text] [Related]

  • 9. Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain.
    Park H, Kim D, Kim E, Sa JK, Lee HW, Yu S, Oh J, Kim SH, Yoon Y, Nam DH.
    Int J Mol Sci; 2017 Sep 13; 18(9):. PubMed ID: 28902178
    [Abstract] [Full Text] [Related]

  • 10. Generation, characterization and preclinical studies of a human anti-L1CAM monoclonal antibody that cross-reacts with rodent L1CAM.
    Cho S, Park I, Kim H, Jeong MS, Lim M, Lee ES, Kim JH, Kim S, Hong HJ.
    MAbs; 2016 Sep 13; 8(2):414-25. PubMed ID: 26785809
    [Abstract] [Full Text] [Related]

  • 11. TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism.
    Canè S, Van Snick J, Uyttenhove C, Pilotte L, Van den Eynde BJ.
    J Immunother Cancer; 2021 Feb 13; 9(2):. PubMed ID: 33637600
    [Abstract] [Full Text] [Related]

  • 12. Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome.
    Cook JR, Clayton NP, Carta L, Galatioto J, Chiu E, Smaldone S, Nelson CA, Cheng SH, Wentworth BM, Ramirez F.
    Arterioscler Thromb Vasc Biol; 2015 Apr 13; 35(4):911-7. PubMed ID: 25614286
    [Abstract] [Full Text] [Related]

  • 13. Improved antibody-based ricin neutralization by affinity maturation is correlated with slower off-rate values.
    Rosenfeld R, Alcalay R, Mechaly A, Lapidoth G, Epstein E, Kronman C, J Fleishman S, Mazor O.
    Protein Eng Des Sel; 2017 Sep 01; 30(9):611-617. PubMed ID: 28472478
    [Abstract] [Full Text] [Related]

  • 14. Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism.
    Van Aarsen LA, Leone DR, Ho S, Dolinski BM, McCoon PE, LePage DJ, Kelly R, Heaney G, Rayhorn P, Reid C, Simon KJ, Horan GS, Tao N, Gardner HA, Skelly MM, Gown AM, Thomas GJ, Weinreb PH, Fawell SE, Violette SM.
    Cancer Res; 2008 Jan 15; 68(2):561-70. PubMed ID: 18199553
    [Abstract] [Full Text] [Related]

  • 15. Characterization of neutralizing affinity-matured human respiratory syncytial virus F binding antibodies in the sub-picomolar affinity range.
    Canziani GA, Melero JA, Lacy ER.
    J Mol Recognit; 2012 Mar 15; 25(3):136-46. PubMed ID: 22407977
    [Abstract] [Full Text] [Related]

  • 16. Expression, purification and characterization of BG(E)RII: a novel pan-TGFbeta inhibitor.
    Verona EV, Tang Y, Millstead TK, Hinck AP, Agyin JK, Sun LZ.
    Protein Eng Des Sel; 2008 Jul 15; 21(7):463-73. PubMed ID: 18499679
    [Abstract] [Full Text] [Related]

  • 17. A combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2 (CXCR2).
    Boshuizen RS, Marsden C, Turkstra J, Rossant CJ, Slootstra J, Copley C, Schwamborn K.
    MAbs; 2014 Jul 15; 6(6):1415-24. PubMed ID: 25484047
    [Abstract] [Full Text] [Related]

  • 18. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, Eser M, McAleese F, Molkenthin V, Gall FL, Topp M, Little M, Zhukovsky EA.
    MAbs; 2015 Jul 15; 7(3):584-604. PubMed ID: 25875246
    [Abstract] [Full Text] [Related]

  • 19. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.
    Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, Blakey DC, Tabrizi M, Jallal B, Trail PA, Coats S, Bosslet K, Chang YS.
    Cancer Res; 2011 Feb 01; 71(3):1029-40. PubMed ID: 21245093
    [Abstract] [Full Text] [Related]

  • 20. A Potent Pan-TGFβ Neutralizing Monoclonal Antibody Elicits Cardiovascular Toxicity in Mice and Cynomolgus Monkeys.
    Mitra MS, Lancaster K, Adedeji AO, Palanisamy GS, Dave RA, Zhong F, Holdren MS, Turley SJ, Liang WC, Wu Y, Meng YG, Vernes JM, Schutten MM.
    Toxicol Sci; 2020 May 01; 175(1):24-34. PubMed ID: 32077954
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 10.